Immunogen (IMGN) Posts Q4 Loss of 71c/Share

Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.71), $0.36 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $12.61 million versus the consensus estimate of $15.42 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Dingdong (DDL) Reports Q2 EPS of RMB0.90